Jamie Cesanek

Articles

Adding abiraterone to ADT/docetaxel may be new standard in de novo mCSPC

September 20, 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.